Regen BioPharma Issues 77.8M Shares, Diluting Existing Holders by 36% to Settle Debt
Summary
Regen BioPharma Inc. issued 77.8 million common shares, representing a 36.7% increase in outstanding shares, to satisfy $68,723 in convertible debt and fees, significantly diluting existing shareholders.
Key Events
-
Significant Share Issuance
Regen BioPharma issued 77,849,847 common shares between February 4 and February 27, 2026.
-
Debt Conversion
The shares were issued to satisfy $53,474 of principal convertible indebtedness, $4,249 of accrued interest, and $11,000 in fees, totaling $68,723.
-
Substantial Dilution
This issuance represents a 36.7% increase in the company's outstanding common shares, which now total 212,318,424 as of March 3, 2026.
-
Ongoing Financial Challenges
This dilutive financing occurs in the context of the company's previously reported 'going concern' doubts, indicating continued financial strain.
Analysis
This filing details a substantial dilutive event for Regen BioPharma, where the company converted $68,723 of convertible debt and accrued interest into 77.8 million common shares. This transaction increases the total outstanding shares by approximately 36.7%, which is a significant dilution for existing shareholders. While the conversion addresses some of the company's liabilities, it comes at a high cost to equity holders, especially given the company's previously disclosed 'going concern' doubts. This move highlights the company's ongoing struggle to manage its financial obligations and secure capital, often resorting to highly dilutive methods.
At the time of this filing, RGBP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $129.5K. The 52-week trading range was $0.00 to $0.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.